Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.75 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753109 | 0.88 | ALDH1A1 (0.68) | HPGDPDE4DLMNAMAPK1ALDH1A1 | |
| SCHEMBL4506277 | 0.86 | LMNA (0.65) | HPGDPDE4DLMNAMAPK1ALDH1A1 | |
| SCHEMBL6052561 | 0.86 | PDE4D (0.64) | HPGDPDE4DLMNAMAPK1ALDH1A1 | |
| SCHEMBL6069548 | 0.86 | PDE4D (1.00) | PDE4DALDH1A1MAPTPDE4BRAB9A | |
| SCHEMBL3611588 | 0.85 | LMNA (0.74) | HPGDPDE4DLMNAMAPK1ALDH1A1 | |
| SCHEMBL13858518 | 0.85 | LMNA (0.82) | HPGDPDE4DLMNAMAPK1ALDH1A1 | |
| SCHEMBL20553225 | 0.85 | PDE4D (0.77) | HPGDPDE4DLMNAMAPK1ALDH1A1 | |
| SCHEMBL20551683 | 0.85 | PDE4D (0.55) | HPGDPDE4DLMNAMAPK1ALDH1A1 | |
| SCHEMBL1753047 | 0.84 | ALDH1A1 (0.66) | HPGDPDE4DLMNAMAPK1ALDH1A1 | |
| SCHEMBL18172116 | 0.84 | PDE4B (0.58) | HPGDPDE4DLMNAMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414056-B2 | Pyrazole-amide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414056-B2 | Pyrazole-amide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-7390810-B2 | Pyrazole-amine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390810-B2 | Pyrazole-amine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-24 | — | — | US | disclosed |
| US-20080108626-A1 | (5-amino-1-phenyl-1H-pyrazole)-(3-Amino-N-isoxazol-3-yl-4-methyl)-benzamide; p38 mitogen-activated protein kinase inhibitor; reduced levels of TNF- alpha expression; antiinfammatory agent: rheumatoid arthritis, psoriasis, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080108626-A1 | (5-amino-1-phenyl-1H-pyrazole)-(3-Amino-N-isoxazol-3-yl-4-methyl)-benzamide; p38 mitogen-activated protein kinase inhibitor; reduced levels of TNF- alpha expression; antiinfammatory agent: rheumatoid arthritis, psoriasis, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20060128729-A1 | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108626-A1 | (5-amino-1-phenyl-1H-pyrazole)-(3-Amino-N-isoxazol-3-yl-4-methyl)-benzamide; p38 mitogen-activated protein kinase inhibitor; reduced levels of TNF- alpha expression; antiinfammatory agent: rheumatoid arthritis, psoriasis, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease | MAPK1, MAPK3, TNF | HPGD 2141/4885PDE4D 1316/4885LMNA 2312/4885 |
| US-20060128729-A1 | Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them | HPSE, ENGASE, UGCG | HPGD 299/4885PDE4D 3307/4885LMNA 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.